Which non-statin cholesterol-lowering options are available?
If you can’t take a statin, don’t tolerate one, or need extra lowering beyond a statin dose, clinicians commonly use other cholesterol-lowering drug classes. The non-statin options generally target LDL cholesterol (the “bad” cholesterol) through different mechanisms.
Ezetimibe (Zetia): the most common add-on or substitute
Ezetimibe lowers cholesterol absorption in the intestines. It’s often used when:
- you want a statin-sparing option, or
- you need additional LDL lowering on top of a statin.
It tends to be a moderate LDL-lowering option compared with the strongest non-statin drugs.
PCSK9 inhibitors (e.g., evolocumab, alirocumab): strong LDL lowering
PCSK9 inhibitors are injectable medicines that increase the liver’s ability to remove LDL cholesterol from the blood. They are typically considered for people with:
- familial hypercholesterolemia, or
- high cardiovascular risk needing substantial LDL reduction, especially when statins (with or without ezetimibe) don’t get LDL low enough, or are not tolerated.
Bempedoic acid (Nexletol) and related therapy (Nexlizet): tablet options
Bempedoic acid is an oral non-statin that works upstream in cholesterol synthesis to reduce LDL cholesterol. It’s usually used for people who need an alternative to statins or additional LDL lowering after other therapies.
There is also combination therapy that pairs bempedoic acid with ezetimibe.
Bile acid sequestrants: older, still used in some cases
Bile acid sequestrants bind bile acids in the gut so the body has to use cholesterol to make more bile acids. They can lower LDL cholesterol, but they often cause gastrointestinal side effects and can affect absorption of other medications.
LDL absorption inhibitor vs. statins: what’s the difference?
- Statins reduce cholesterol production in the liver and change how liver cells take up LDL.
- Ezetimibe reduces cholesterol absorption from the intestine.
- PCSK9 inhibitors increase LDL removal by the liver.
- Bempedoic acid lowers cholesterol synthesis in a different step than statins.
These different mechanisms let clinicians tailor therapy to side effects, drug interactions, and how low LDL needs to go.
“Non-statin” sometimes includes triglyceride-focused drugs—what applies to cholesterol?
Not all non-statin medicines lower LDL meaningfully. Some drugs are mainly for triglycerides (for example, omega-3 fatty acid products or fibrates). If your goal is lowering LDL cholesterol, the most direct non-statin options are the classes above (ezetimibe, PCSK9 inhibitors, bempedoic acid, bile acid sequestrants).
What should you ask your clinician before switching?
Important practical questions include:
- What is your LDL goal based on your cardiovascular risk?
- Which non-statin option fits your history (statin intolerance type, prior side effects)?
- Are you on other medicines that could interact (especially with bile acid sequestrants)?
- Do you need LDL lowering only, or also triglyceride reduction?
Where do patents and manufacturers matter for availability?
If you’re trying to find which companies make specific non-statin cholesterol drugs or how their exclusivity/patents are positioned, DrugPatentWatch.com can help track branded products and patent activity. (For example, it tracks information across injectable and oral therapies.) You can search relevant non-statin cholesterol drugs there: DrugPatentWatch.com
Sources
- DrugPatentWatch.com